The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
Abstract
Between September 1986 and March 1988, 33 patients with refractory germ cell cancer were entered on a phase I/II trial of two courses of high-dose carboplatin plus etoposide with autologous bone marrow support. All patients had extensive prior treatment and had either cisplatin-refractory disease (67%) defined as progression within 4 weeks of the last cisplatin dose or failed at least two cisplatin-based regimens (35%) including a cisplatin-ifosfamide salvage regimen. Patients received a fixed total dose of etoposide of 1,200 mg/m2 with each cycle. The carboplatin dose ranged from 900 mg/m2 to 2,000 mg/m2. Twenty of the 33 patients received the second cycle of therapy. Despite extensive prior therapy with cisplatin, neurotoxicity, nephrotoxicity, or hearing impairment with high-dose carboplatin and etoposide was unusual. The most common nonhematologic toxicity was moderate enterocolitis. The hematologic toxicity of this regimen was substantial at each dose level. All 53 courses were accompanied by granulocytopenic fevers. Seven of the 33 patients (21%) died from treatment. All of these deaths occurred during the granulocyte nadir, and five were related to documented sepsis. Overall, 14 of 32 patients (44%) evaluable for response obtained an objective response, including eight complete remissions. Four patients remain in complete remission, with three patients being continuously free of disease in excess of 1 year. Eight responders (including four complete remissions) had progressed while receiving cisplatin. We conclude that carboplatin and etoposide can be administered in combination at high dosages and this regimen may have curative potential for patients with germ cell tumors resistant to conventional-dose cisplatin-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Self-citationEinhorn, L. H. (1981) · PubMed · Cited by 338
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer, P. J., Einhorn, L. H., & Williams, S. D. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.4.528 · Cited by 175
Self-citationUeda, H., Takenawa, T., Millan, J. C., Gesell, M. S., & Brandes, D. W. (1980) · Cancer · doi:10.1002/1097-0142(19801115)46:10<2154::aid-cncr2820461008>3.0.co;2-3 · Cited by 50
Cited by
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Self-citationBroxmeyer, H. E., Hangoc, G., Cooper, S., Ribeiro, R. C., Graves, V, Yoder, M., Wagner, J., Vadhan-Raj, S., Benninger, L., & Rubinstein, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4109 · Cited by 490
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
Beyer, J., Kramar, A., Mandanas, R., Linkesch, W., Greinix, A., Droz, J. P., Pico, J. L., Diehl, A., Bokemeyer, C., Schmoll, H. J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2638 · Cited by 323
Self-citationNichols, C. R., Williams, S. D., Loehrer, P. J., Greco, F. A., Crawford, E. D., Weetlaufer, J., Miller, M. E., Bartolucci, A., Schacter, L., & Einhorn, L. H. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1163 · Cited by 288
Self-citationLorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., De Giorgi, U., Fléchon, A., Margolin, K., Lotz, J.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6678 · Cited by 273
Recent advances in management of patients with platinum‐refractory testicular germ cell tumors
Kollmannsberger, C., Nichols, C., & Bokemeyer, C. (2006) · Cancer · doi:10.1002/cncr.21742 · Cited by 77
“responsive to the treatment.(5,7) Identifying new treatment options with significant antitumor activity in these young patients with refractory disease remains a priority.”
BackgroundSelf-citation
Metadata
- Authors
- Nichols, C. R., Tricot, G., Williams, S. D., van Besien, K., Loehrer, P. J., Roth, B. J., Akard, L., Hoffman, R., Goulet, R., & Wolff, S. N.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-07
- Volume
- 7
- Issue
- 7
- Pages
- 932-939
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1829527967
- Cited by
- 353
- References
- 5
- FWCI
- 34.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.